Research programme: calcium-sensing receptor antagonists - NPS Pharmaceuticals/GlaxoSmithKlineAlternative Names: Calcilytics - NPS Pharmaceuticals/GlaxoSmithKline; NPS 2143; NPS 89636; SB-262470; SKF 45675
Latest Information Update: 10 Aug 2011
At a glance
- Originator NPS Pharmaceuticals
- Class Naphthalenes; Pyrimidinones; Small molecules
- Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postmenopausal osteoporosis